Metabolic syndrome in drug-naïve first-episode psychosis treated with atypical antipsychotics.
Sahoo
Saddichha
S
Ameen
Shahul
S
Akhtar
Sayeed
S
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D003430:Cross-Sectional Studies; D003987:Dibenzothiazepines / Q000009:adverse effects / Q000627:therapeutic use; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D024821:Metabolic Syndrome / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology; D000077152:Olanzapine; D000069348:Quetiapine Fumarate; D018967:Risperidone / Q000009:adverse effects / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy* / Q000453:epidemiology; D012563:Schizophrenia, Paranoid / Q000188:drug therapy* / Q000453:epidemiology; D014280:Triglycerides / Q000097:blood; D049629:Waist-Hip Ratio
D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D014280:Triglycerides; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; D018967:Risperidone; D000077152:Olanzapine